Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trius Antibiotic Tedizolid Hits Old, New And In-Between Endpoints

Executive Summary

Tedizolid, a next-generation antibiotic from the same class as Pfizer’s Zyvox, has met all complicated skin infection endpoints for both a U.S. and European filing, and Trius plans submissions in second half 2013 and first half 2014, respectively. European partnering talks, meanwhile, have gained new intensity.

Advertisement

Related Content

Cubist Tedizolid Advisory Cmte. Review Will Gauge FDA’s Mood On Antibiotic “Breakpoints”
Next Up For Cubist: A Future That Includes Optimer, Trius
Cubist’s Time To Shine: Antibiotic Specialist Acquires Optimer, Trius
Antibiotic Market Snapshot: In Exchange For Higher Prices, More Value
PhRMA Urges FDA To Set Non-Inferiority Margin For Skin Infection Drugs
FDA's New Skin Infection Endpoint Needs Refinement, Advisory Panel Says
Trius Confident After Phase II Results Against Skin Infections That Include MRSA

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055238

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel